A new study supports previous data demonstrating the superiority of prasugrel over ticagrelor in reducing the composite outcome of mortality, myocardial infarction, or stroke in patients with acute ...
The US Food and Drug Administration (FDA) has approved ustekinumab -kfce (Yesintek) as a biosimilar to ustekinumab (Stelara) for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis, ...